(28 days)
No
The description focuses on the electromechanical and magnetic stimulation principles of the device, with no mention of AI or ML in the device description, intended use, or performance studies.
Yes
The device is indicated for the "treatment of Major Depressive Disorder," which is a therapeutic purpose.
No
The device description clearly states its purpose is for treatment, not diagnosis: "The MagVita TMS Therapy System is indicated for the treatment of Major Depressive Disorder..." and "The Mag Vita TMS Therapy System is a computerized, electromechanical medical device that produces and delivers non-invasive, magnetic fields to induce electrical currents directed at regions of the cerebral cortex."
No
The device description explicitly states it is a "computerized, electromechanical medical device" that "produces and delivers non-invasive, magnetic fields" and involves hardware components like a capacitor and stimulating coil. This indicates it is a hardware device with software control, not a software-only device.
Based on the provided information, the Mag Vita TMS Therapy System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Mag Vita TMS Therapy System Function: The description clearly states that the Mag Vita TMS Therapy System is a device that delivers magnetic fields to induce electrical currents directly to the brain (cerebral cortex, DLPFC). It is a therapeutic device used for treatment, not for analyzing biological samples.
- Intended Use: The intended use is for the treatment of Major Depressive Disorder, not for diagnosing or analyzing a condition based on a sample.
Therefore, the Mag Vita TMS Therapy System is a therapeutic medical device, not an IVD.
N/A
Intended Use / Indications for Use
The Mag Vita TMS Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to recieve satisfactory improvement from prior antidepressant medication in the current episode
Product codes
OBP
Device Description
The MagVita TMS Therapy System is a computerized, electromechanical medical device that produces and delivers non-invasive, magnetic fields to induce electrical currents directed at regions of the cerebral cortex. The Mag Vita TMS Therapy System is indicated for: Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
Transcranial magnetic stimulation (TMS) is a non-invasive technique for stimulating brain and neural tissue. The principle of magnetic stimulation is implicit in Faraday's law. The pulses of current are generated with a circuit containing a capacitor connected to the stimulating coil. With the capacitor charged to a certain level, the conducting state will cause the discharging of the capacitor through the coil. A magnetic field is generated proportional to this current. The rapid change in the magnetic field induces a current in conducting materials e.g. the body tissue. If the current induced in the human body is of sufficient amplitude and duration, it will excite neurons.
In the MagVita TMS therapy system TMS pulses are applied repetitively at a frequency of 10Hz. Such stimulation has been shown to be effective in modulating cortical excitability. The observed and documented increase in cortical excitability after high frequency (10Hz) repetitive transcranial magnetic stimulation has been shown to persist beyond the duration of the train of stimulation. Repetitive Magnetic stimulation with the MagVita TMS therapy system is applied to the human brain on the left dorsolateral prefrontal cortex (DLPFC).
- MagPro Stimulator and Trolley
- Coil for MT determination
- Marking apparatus for locating treatment area
- Patient head fixation
- Coil for Depression Treatment
- Isolation Transformer
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
left dorsolateral prefrontal cortex (DLPFC)
Indicated Patient Age Range
adult patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Non-Clinical performance data: The non-clinical performance testing of the components of the Mag Vita TMS Therapy System has been tested as required, and cleared by the FDA earlier on K091940 and K150641. These tests demonstrate that the Mag Vita TMS Therapy System is safe and effective for use in treatment of Major Depressive Disorder.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.5805 Repetitive transcranial magnetic stimulation system.
(a)
Identification. A repetitive transcranial magnetic stimulation system is an external device that delivers transcranial repetitive pulsed magnetic fields of sufficient magnitude to induce neural action potentials in the prefrontal cortex to treat the symptoms of major depressive disorder without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on any antidepressant therapy.(b)
Classification. Class II (special controls). The special control is FDA's “Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation System.” See § 882.1(e) for the availability of this guidance document.
0
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 16, 2017
Tonica Elektronik A/S Lise Terkelsen QA/RA Manager Lucernemarken 15 Farum, 3520 Dk
Re: K171481
Trade/Device Name: MagVita TMS Therapy System Regulation Number: 21 CFR 882.5805 Regulation Name: Repetitive transcranial magnetic stimulation system Regulatory Class: Class II Product Code: OBP Dated: May 17, 2017 Received: May 19, 2017
Dear Lise Terkelsen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device
1
related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
William J. Heetderks -S 2017.06.16 12:07:00 -04'00'
for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K171481
Device Name MagVita TMS Therapy System
Indications for Use (Describe)
The Mag Vita TMS Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to recieve satisfactory improvement from prior antidepressant medication in the current episode
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
Submitter's Information
| Name of 510(k) owner: | Tonica Elektronik A/S
Lucernemarken 15
DK-3520 Farum, Denmark | | |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Phone: | +45 4499 8444 | | |
| Fax: | +45 4499 1544 | | |
| Contact person: | Lise Terkelsen
Email: lise.terkelsen@tonica.dk | | |
| Preparation date: | May 15, 2017 | | |
| Trade name: | MagVita TMS Therapy System | | |
| Common name: | Transcranial Magnetic Stimulator | | |
| Classification name: | Repetitive Transcranial Magnetic Stimulator for treatment of
Major Depressive Disorder [21 CFR 882.5805, Product Code
OBP] | | |
| Classification: | Class II Medical Device | | |
| Predicate Devices: | Neurostar TMS Therapy System, K160703
MagVita TMS Therapy System, K150641 | | |
| Special Controls: | The 510k submission addressed the special controls required
by regulation and specified in the FDA guidance document
titled "Class II Special Controls Guidance
Document: Repetitive Transcranial Magnetic Stimulation
(rTMS) Systems | | |
4
Device description
The MagVita TMS Therapy System is a computerized, electromechanical medical device that produces and delivers non-invasive, magnetic fields to induce electrical currents directed at regions of the cerebral cortex. The Mag Vita TMS Therapy System is indicated for
Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode
Transcranial magnetic stimulation (TMS) is a non-invasive technique for stimulating brain and neural tissue. The principle of magnetic stimulation is implicit in Faraday's law. The pulses of current are generated with a circuit containing a capacitor connected to the stimulating coil. With the capacitor charged to a certain level, the conducting state will cause the discharging of the capacitor through the coil. A magnetic field is generated proportional to this current. The rapid change in the magnetic field induces a current in conducting materials e.g. the body tissue. If the current induced in the human body is of sufficient amplitude and duration, it will excite neurons.
In the MagVita TMS therapy system TMS pulses are applied repetitively at a frequency of 10Hz. Such stimulation has been shown to be effective in modulating cortical excitability. The observed and documented increase in cortical excitability after high frequency (10Hz) repetitive transcranial magnetic stimulation has been shown to persist beyond the duration of the train of stimulation. Repetitive Magnetic stimulation with the MagVita TMS therapy system is applied to the human brain on the left dorsolateral prefrontal cortex (DLPFC).
- MagPro Stimulator and Trolley .
- MagPro family o
- Trolley with holding arrangements o
- Coil for MT determination .
- Coil C-B60 o
- Marking apparatus for locating treatment area .
- Marking plate for Coil C-B60 o
- Pen for marking. Cap, Ruler o
- Patient head fixation .
- Treatment Chair o
- Vacuum Pump and Vacuum pillow o
- Super Flexible Arm mounted on the trolley o
- Coil for Depression Treatment .
- Coil Cool-B65 with Coil Cooler unit o
- Isolation Transformer •
5
Intended Use/Indication for Use:
Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
Standards:
The MagVita TMS Therapy System has been tested and complies with the following standards
- ISO 13485:2012 .
- IEC60601-1 •
- IEC60601-1-1 .
- IEC60601-1-2 .
Non-Clinical performance data:
The non-clinical performance testing of the components of the Mag Vita TMS Therapy System has been tested as required, and cleared by the FDA earlier on K091940 and K150641.
These tests demonstrate that the Mag Vita TMS Therapy System is safe and effective for use in treatment of Major Depressive Disorder.
Substantial equivalence:
The MagVita TMS Therapy System is substantially equivalent to the predicate devices (our own MagVita TMS Therapy System and Neurostar TMS). The MagVita TMS Therapy System and the predicate devices have identical intended use /indication for use, and technological characteristics. The principles of operation, the output stimulation parameters and the materials are equivalent to the predicates. The modification to the device allows a range of inter-train intervals from 11 to 26 seconds, rather than the fixed 26 second duration, which will allow a reduction in treatment time from 37.5 minutes to a minimum of 18.8 minutes.
The MagVita TMS Therapy System and the predicate devices are all indicated for
Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
Design of the MagVita TMS Therapy System is similar to the predicate device as both systems apply Transcranial Magnetic Stimulation as repetitive pulse trains at 10Hz delivered as brief rapidly alternating magnetic fields to induce electrical currents over the prefrontal cortex.
Both the MagVita TMS Therapy System and the predicate devices have the same components consisting of TMS stimulator with software, electromagnetic coil and an articulated arm for positioning of the treatment coil. The operational procedures including system setup, patient preparations, motor threshold determination, coil
6
positioning and treatment with predefined treatment stimulation parameters are essentially the same.
| Criteria | MagVita TMS Therapy
System | MagVita TMS Therapy
System (K150641) | NeuroStar TMS Therapy
System (K160703) | |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| Performance | Waveforms: Biphasic.
Frequency: 0.1 -30 pulses per
second or 0.1 -100 pulses,
depending on model | Waveforms: Biphasic.
Frequency: 0.1 -30 pulses per
second or 0.1 -100 pulses,
depending on model | Waveforms: Biphasic
Frequency: 0.1 -30 pulses per
second. | |
| | Recommended standard
treatment:
Stimulation Intensity: 120% MT
Repetition rate:10 Hz
Train duration: 4 sec
Inter-train interval: 11-26 sec
Pulses/session: 3000
Treatment duration: 18.8 min. | Recommended standard
treatment:
Stimulation Intensity: 120% MT
Repetition rate: 10 Hz
Train duration: 4 sec
Inter-train interval: 26 sec
Pulses/session: 3000
Treatment duration: 37 min. | Recommended standard
treatment:
Stimulation Intensity: 120% MT
Repetition rate: 10 Hz
Train duration: 4 sec
Inter-train interval: 11-26 sec
Pulses/session: 3000
Treatment duration: 18.8 min. | |
| | Output Stimulation Parameters:
Amplitude in Standard Motor
Threshold (SMT) units :
0 - 1.7 | Output Stimulation Parameters:
Amplitude in Standard Motor
Threshold (SMT) units:
0 - 1.7 | Output Stimulation Parameters:
Amplitude in Standard Motor
Threshold (SMT) units:
0.22 - 1.6 | |
| | Pulse width:
290 μs, Biphasic sinusoid
waveform. | Pulse width:
290 μs, Biphasic sinusoid
waveform. | Pulse width:
185 μs (±10%), Biphasic
sinusoid waveform.. | |
| | Frequency Range:
0.1-30 pps or 0.1-100 pps,
depending on model | Frequency Range:
0.1-30 pps or 0.1-100 pps,
depending on model | Frequency Range:
0.1-30 pps | |
| | Coil
Configuration | Figure-of-eight coil
Air core | Figure-of-eight coil
Air core | Figure-of-eight coil
Ferromagnetic core |
| | Cooling | Liquid cooling | Liquid cooling | Ferrofluidic cooling |
| | Standards met | Company complies with ISO
13485:2012. | Company complies with ISO
13485:2012 | Company complies with ISO
13485:2003 |
| | Electrical safety | Complies with IEC60601-1 3rd
edition, and IEC60601-1-2. | Complies with IEC60601-1 3rd
edition, and IEC60601-1-2. | Complies with IEC60601-1 and
IEC60601-1-2. |
Characteristics of the Device as Compared to Predicate Devices
Conclusion:
The above comparison, demonstrates and supports the substantial equivalency of the MagVita TMS Therapy System to our own MagVita TMS Therapy System and the NeuroStar TMS Therapy System.
The indication for use, the target population, the dosage, the treatment procedure, the treatment position and all relevant protocol parameters (intensity, repetition rate, number of pulses in a train, numbers of trains, number of treatment sessions) are identical for the MagVita TMS Therapy System and the predicate devices.
7
The transducer design (figure-of-eight) are equivalent and the realized magnetic properties of the MagVita TMS Therapy System and the predicate devices are substantial equivalent.
The reliability of the positioning method used by the MagVita TMS Therapy System is, based on the direct relationship of the underlying cortical brain anatomy to the patient's scalp, as is the method used in the predicate devices. The method for identifying the correct treatment position in the Mag Vita TMS Therapy System is at least as effective as the method employed by the predicate devices.
On the basis of the only modification of the treatment parameter, the MagVita TMS Therapy System does not introduce any new safety considerations in comparison to the predicate devices
All other identified differences between the three systems are minor and without impact on safety or efficacy.